Daxor Corporation announced new data from Banner University Medicine Advanced Heart Failure Clinic in Phoenix, AZ validating the benefits of the Company's BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure. Data were presented at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), which brought together the world's leading experts in heart failure at the Huntington Convention Center in Cleveland, OH on October 8, 2023. Key findings included: The urgent need for BVA to guide care was shown by the discordance between clinician estimates of total and red blood cell volumes and measured volumes was present in 48% of the patients for total blood volume and in 64% of patients for red blood cell volume in the initial twenty-five patie nts.

Most patients had severe blood volume derangements as measured with BVA, only 41% of patients had normal total blood volume, and only 29% had normal red blood cell volume. BVA optimized care and led to better outcomes In the study's outpatient advanced heart failure clinic, incorporating BVA allowed diagnosis of common, often severe, and clinicallypected variances in total blood and red blood cell volumes. The study titled, "The Value of Blood Volume Analysis to Guide Ambulatory Advanced Heart Failure Care," measured individual blood volumes in eighty-three ambulatory patients with advanced heart Failure utilizing BVA to determine the benefits of quantitative blood volume measurements not otherwise obtainable using traditional methods such as clinical signs, symptoms, and exam.